PL2480255T3 - Terapia przewlekłych zakażeń jelitowych - Google Patents

Terapia przewlekłych zakażeń jelitowych

Info

Publication number
PL2480255T3
PL2480255T3 PL10818479T PL10818479T PL2480255T3 PL 2480255 T3 PL2480255 T3 PL 2480255T3 PL 10818479 T PL10818479 T PL 10818479T PL 10818479 T PL10818479 T PL 10818479T PL 2480255 T3 PL2480255 T3 PL 2480255T3
Authority
PL
Poland
Prior art keywords
therapy
enteric infections
chronic enteric
chronic
infections
Prior art date
Application number
PL10818479T
Other languages
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Thomas Julius Borody
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Julius Borody filed Critical Thomas Julius Borody
Publication of PL2480255T3 publication Critical patent/PL2480255T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10818479T 2009-09-23 2010-09-22 Terapia przewlekłych zakażeń jelitowych PL2480255T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24527709P 2009-09-23 2009-09-23
EP10818479.7A EP2480255B1 (en) 2009-09-23 2010-09-22 Therapy for chronic enteric infections
PCT/IB2010/002377 WO2011036539A1 (en) 2009-09-23 2010-09-22 Therapy for enteric infections

Publications (1)

Publication Number Publication Date
PL2480255T3 true PL2480255T3 (pl) 2018-07-31

Family

ID=43795455

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10818479T PL2480255T3 (pl) 2009-09-23 2010-09-22 Terapia przewlekłych zakażeń jelitowych

Country Status (9)

Country Link
US (3) US20120177650A1 (pl)
EP (1) EP2480255B1 (pl)
JP (1) JP2013505289A (pl)
CN (1) CN102711819A (pl)
AU (3) AU2010299552A1 (pl)
CA (1) CA2775050C (pl)
ES (1) ES2660008T3 (pl)
PL (1) PL2480255T3 (pl)
WO (1) WO2011036539A1 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63299B1 (sr) 2010-02-01 2022-07-29 Rebiotix Inc Bakterioterapija clostridium difficile kolitisa
AU2011242574B2 (en) * 2010-04-23 2016-09-29 Chr. Hansen A/S Prevention and treatment of gastrointestinal infection in mammals
DE102011006781A1 (de) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
US20120276056A1 (en) * 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
NZ714516A (en) * 2012-03-02 2017-06-30 Regeneron Pharma Human antibodies to clostridium difficile toxins
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
PL3628161T3 (pl) 2012-11-23 2023-08-07 Seres Therapeutics, Inc. Synergistyczne kompozycje bakteryjne i sposoby ich wytwarzania oraz stosowanie
CN103007046B (zh) * 2012-12-25 2014-11-05 浙江农林大学 一种预防肠道疾病的灌肠液及其用途
HK1219022A1 (zh) 2013-02-04 2017-03-24 Seres Therapeutics, Inc. 填充胃肠道的方法
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
US10513552B2 (en) * 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
WO2016059161A1 (en) * 2014-10-15 2016-04-21 Xenothera Composition with reduced immunogenicity
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
SE1550189A1 (en) * 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
HK1252460A1 (zh) 2015-05-14 2019-05-24 Crestovo Holdings Llc 用於糞便菌群移植的組合物以及用於製備和使用它們的方法和用於遞送它們的裝置
CN104857026A (zh) * 2015-05-18 2015-08-26 新乡医学院 酪酸梭菌二联活菌散对小肠结肠预防作用的研究方法
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102066242B1 (ko) 2015-06-09 2020-01-14 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(mrt) 조성물 및 제조 방법
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
SMT202200174T1 (it) 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
CN104961826B (zh) * 2015-07-14 2017-12-05 大连理工大学 一种金黄色葡萄球菌特异性鸡卵黄免疫球蛋白可变区单链抗体及用途
WO2017035188A1 (en) * 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3419638A4 (en) * 2016-02-25 2019-10-02 Thomas Julius Borody COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHRONIC INFECTION DISEASES
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
WO2019087372A1 (ja) * 2017-11-02 2019-05-09 オーストリッチファーマ株式会社 細菌感染症用ダチョウ抗体
CN108220200B (zh) * 2018-02-08 2020-06-23 中国人民解放军军事科学院军事医学研究院 用于治疗结肠炎症的微厌氧细菌及其应用
JP2022513337A (ja) * 2018-10-03 2022-02-07 アヌビス バイオ コーポレーション 動物の腸管感染症及び急性下痢を治療する組成物及び方法
US20200289804A1 (en) 2019-02-21 2020-09-17 Olympus Corporation Flora treatment
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN111345473A (zh) * 2020-03-13 2020-06-30 珠海华敏医药科技有限公司 一种含卵黄抗体IgY的益生菌组合物及应用制剂
TW202146036A (zh) * 2020-04-28 2021-12-16 香港中文大學 針對ｃｏｖｉｄ－１９的微生物的治療和診斷用途
KR102732549B1 (ko) * 2022-01-20 2024-11-19 서강대학교 산학협력단 비브리오 패혈증 예방용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509965A (ja) * 1993-03-15 1996-10-22 ファーマ・パシフィック・ピーティーワイ・リミテッド 治療剤および治療方法
AU7966694A (en) * 1993-07-21 1996-05-02 University Of Kentucky Research Foundation, The A multicompartment hard capsule with control release properties
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
KR100387245B1 (ko) * 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
CZ287989B6 (cs) * 1998-03-20 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat
WO2000024266A2 (en) * 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품
JP3946143B2 (ja) * 2001-01-05 2007-07-18 イージージーバイオテク インコーポーレーション 抗−混合菌免疫蛋白質を保有した卵の生産方法
US20050266069A1 (en) * 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
WO2005005481A2 (en) * 2003-07-10 2005-01-20 Avitek Pharma Inc. Combination therapy for gastroenteric diseases caused by microorganisms
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics

Also Published As

Publication number Publication date
ES2660008T3 (es) 2018-03-20
AU2016231612A1 (en) 2016-10-20
AU2018256633A1 (en) 2018-11-22
EP2480255A1 (en) 2012-08-01
US20180155410A1 (en) 2018-06-07
EP2480255B1 (en) 2017-11-22
US20120177650A1 (en) 2012-07-12
EP2480255A4 (en) 2013-03-20
JP2013505289A (ja) 2013-02-14
AU2010299552A1 (en) 2012-04-05
US20190276518A1 (en) 2019-09-12
CA2775050C (en) 2020-07-14
CN102711819A (zh) 2012-10-03
WO2011036539A1 (en) 2011-03-31
CA2775050A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
PL2480255T3 (pl) Terapia przewlekłych zakażeń jelitowych
PL2493471T3 (pl) Nowa skojarzona terapia jelitowa
IL216912A0 (en) Peptide therapy for increasing platelet levels
GB201709797D0 (en) Novel parasite therapy
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
GB0900599D0 (en) Treatment
EP2624841A4 (en) COMPOSITIONS FOR TREATING CHRONIC VIRAL INFECTIONS
EP2514449A4 (en) hemodialyzer
GB201005394D0 (en) Therapy
GB0922351D0 (en) Orthogonal Q-Ribosomes
GB0913968D0 (en) Treatment
GB0916997D0 (en) Combination therapy
GB0902916D0 (en) Antibody therapy
GB201001521D0 (en) Treatment
GB0907973D0 (en) Combination therapy
GB0906026D0 (en) Therapeutic compounds
GB0903319D0 (en) Therapy
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903321D0 (en) Therapy
GB0919114D0 (en) Therapeutic intervention
AU5097P (en) Cot-N-Candy Prunus hybrid
GB0903080D0 (en) Compound for therapy
GB0914441D0 (en) Compound for therapy
GB0901497D0 (en) Compound for therapy